Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu)

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu) - References

---

1. Pharmacodynamics & Mechanism of Action

Regenerative signaling peptides accelerate the transition from acute inflammation to proliferative angiogenesis, tenocyte/myoblast migration, and type I/III collagen organization.

• BPC-157 (Body Protection Compound-157; GEPPPGKPADDAGLV): Synthetic pentadecapeptide derived from human gastric juice that remains stable in gastric acid for $>24\text{ hours}$.
  • FAK-Paxillin & GH Receptor Upregulation: Activates Focal Adhesion Kinase (FAK) and paxillin phosphorylation in tendon fibroblasts, accelerating tenocyte outgrowth and upregulating Growth Hormone Receptor (GHR) expression on healing fibroblasts by up to $7\text{-fold}$ (synergizing with GH Secretagogues (Ipamorelin, CJC-1295, Tesamorelin)).
  • VEGFR2 & eNOS Homeostasis: Stimulates VEGFR2 internalization and Akt-eNOS activation to drive collateral angiogenesis in avascular tissues (tendons, ligaments, menisci) while protecting the gastrointestinal mucosa and tight junctions (ZO-1, Claudin-1).
• TB-500 / Thymosin $\beta 4$ (Ac-SDKP active N-terminal domain / 43-AA parent):
  • G-Actin Sequestration & Cytoskeletal Migration: Binds monomeric G-actin ($1:1$ stoichiometry), preventing premature polymerization until endothelial, keratinocyte, and satellite stem cells migrate into the wound bed.
  • Anti-Fibrotic & Cardiac Repair: Downregulates myofibroblast $\alpha$-smooth muscle actin ($\alpha$-SMA) to prevent scar fibrosis while releasing the anti-fibrotic tetrapeptide Ac-SDKP.
• GHK-Cu (Glycyl-L-Histidyl-L-Lysine-${\text{Cu}}^{2+}$): Endogenous human plasma tripeptide ($200\text{ ng/mL}$ at age 20, dropping to $80\text{ ng/mL}$ by age 60) with high copper(II) affinity. Modulates $>4,000$ human genes ($\ge 50\%$ up/down shift in Broad Institute Connectivity Map), resetting senescent fibroblast transcriptomes, balancing MMPs and TIMPs, and stimulating Type I/III collagen, elastin, glycosaminoglycans, and nerve outgrowth.
• KPV (Lys-Pro-Val): C-terminal tripeptide of $\alpha$-MSH; enters intestinal epithelial and immune cells via PepT1 transporters to inhibit NF-$\kappa$B nuclear translocation and mast cell degranulation without causing melanogenesis.

---

2. Pharmacokinetics & Route Selection

Peptide	Molecular Weight	Optimal Route	Systemic vs. Local Action	Stability Profile
BPC-157 (Acetate vs. Arginate)	$1,419\text{ Da}$	SubQ (musculoskeletal) or Oral Arginate (GI lumen)	Systemic (SubQ reaches all tissues); Arginate salt shows $>90\%$ gastric stability	Exceptionally stable in human gastric juice ($>24\text{ h}$)
TB-500 / Thymosin $\beta 4$	$4,963\text{ Da}$ (TB4) / $889\text{ Da}$ fragment	SubQ	Highly systemic (low molecular weight allows rapid interstitial diffusion)	Requires bacteriostatic water reconstitution & $2\text{–}{8}^{\circ }\text{C}$ storage
GHK-Cu	$403.9\text{ Da}$	SubQ (systemic) or Topical/Microneedling (dermal/follicular)	Both systemic ECM remodeling and local dermal collagen synthesis	High stability; SubQ injection can cause transient copper-ion site soreness
KPV	$342.4\text{ Da}$	Oral capsule / SubQ / Intranasal	Absorbed intact via intestinal PepT1 di/tripeptide transporter	Stable orally for IBD / gut barrier protocols

---

3. Dosing, Cycling & Synergies

• Standard Protocol (“The Wolverine Stack”):
  • BPC-157: $250\text{–}500\mu \text{g}$ SubQ twice daily (or $500\mu \text{g}$ oral Arginate salt twice daily for GI barrier repair).
  • TB-500 (Thymosin $\beta 4$): $2.0\text{–}2.5\text{ mg}$ SubQ twice weekly (or $500\mu \text{g/day}$ daily micro-dosing).
  • GHK-Cu: $1.5\text{–}2.0\text{ mg/day}$ SubQ (diluted with extra bacteriostatic water or co-drawn with BPC-157 to eliminate injection-site sting) + $1\text{–}2\%$ topical serum.
• Cycling Cadence: 4 to 8 weeks on, followed by at least 4 weeks off.
• Synergies:
  • Collagen + Vitamin C Loading: Ingest $15\text{–}20\text{ g}$ hydrolyzed collagen peptides (Amino Acids & Precursors) + $50\text{–}100\text{ mg}$ Vitamin C $45\text{ min}$ prior to isometric/eccentric tendon loading while on BPC-157/TB-500.
  • Zinc Balance: Pair systemic GHK-Cu with $15\text{ mg/day}$ Zinc Picolinate/Bisglycinate (at a separate time of day) to maintain optimal serum $\text{Zn:Cu}$ ratio ($1:1$ to $1.2:1$).
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Active malignancy or history of angiogenesis-sensitive tumors (pathological VEGF and actin polymerization pathways can theoretically promote tumor neovascularization); proliferating diabetic retinopathy; WADA-tested athletes (BPC-157 and TB-500 are prohibited under WADA S0/S2).
  • Biomarkers: hs-CRP, ESR, Serum Copper & Ceruloplasmin, Plasma Zinc, and VEGF (if monitoring angiogenesis).

---

4. Key Scientific Evidence Summary

• Tendon Fibroblast Migration & FAK-Paxillin: Chang et al. (2011) demonstrated in Journal of Applied Physiology that BPC-157 dose-dependently accelerated tendon explant outgrowth, enhanced cell survival under oxidative stress, and activated FAK-paxillin phosphorylation.
• ** Tendon GH Receptor Upregulation:** Chang et al. (2014) published in Molecules that BPC-157 increased Growth Hormone Receptor (GHR) mRNA and protein expression on tendon fibroblasts by up to 7-fold, potentiating GH-induced proliferation.
• GHK-Cu Transcriptomic Reset: Pickart & Margolina (2018) detailed Broad Institute Connectivity Map data showing GHK-Cu modulates $31.2\%$ of the human genome ($\ge 50\%$ expression shift in $4,096$ genes), suppressing metastatic/inflammatory genes while upregulating DNA repair and extracellular matrix remodeling.

See full study breakdowns in Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu) - References.